Company Focus
AstraZeneca
Latest AstraZeneca News
Pharmaceutical
Once seen as a niche tool for rare tumors, theranostics is quickly becoming a new standard in cancer care. Combining diagnostics and therapy in a single platform, the field has drawn billions in pharma investment and sparked regulatory momentum, as precision imaging begins to guide not only what patients receive—but when, how often, and with what expected impact. 18 July 2025
Related News
Insights
Company Spotlight
A clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics.
Latest News & Features of interest to AstraZeneca
Pharmaceutical
Once seen as a niche tool for rare tumors, theranostics is quickly becoming a new standard in cancer care. Combining diagnostics and therapy in a single platform, the field has drawn billions in pharma investment and sparked regulatory momentum, as precision imaging begins to guide not only what patients receive—but when, how often, and with what expected impact. 18 July 2025
Biotechnology
French biotech One Biosciences has raised 15 million euros ($16 million) in series A financing to advance development of its clinical-grade single-cell tumor profiling technology. 17 July 2025
Pharmaceutical
The Bristol Myers Squibb-Pfizer Alliance today announced a new direct-to-patient option for purchasing Eliquis (apixaban) via their Alliance’s patient resource Eliquis 360 Support. 17 July 2025
Biotechnology
US companies SandboxAQ and iOncologi have announced a strategic collaboration to jointly develop, validate, and commercialize a novel high-fidelity mRNA vaccine for glioblastoma, the most common and aggressive malignant brain tumor in adults. 17 July 2025
Biotechnology
Swiss pharma giant Roche has won approval from the UK’s Medicines and Healthcare Regulatory Agency (MHRA) for its combination treatment of Columvi (glofitamab) alongside gemcitabine and oxaliplatin (GemOx) for adults with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) not otherwise specified who are ineligible for autologous stem cell transplant. 17 July 2025
Pharmaceutical
The UK’s National Institute for Health and Care Excellence (NICE) has recommended Novartis’ Kisqali (ribociclib) as an adjuvant treatment for all eligible populations of HR+/HER2- early breast cancer patients. 17 July 2025
Biotechnology
US rare disease meds developer Sarepta Therapeutics late yesterday announced a strategic restructuring plan designed to prioritize high-value, high impact programs, meet its 2027 financial obligations, and support its long-term financial viability. 17 July 2025
Pharmaceutical
Swiss pharma giant Novartis this morning reported second quarter 2025 financial results, showing that net sales were $14.1 billion (+12%, +11% cc), with volume contributing 12 percentage points to growth. This was slightly better than the consensus estimate of $14.02 billion. 17 July 2025
Pharmaceutical
Bayer is giving chief executive Bill Anderson more time to deliver on his ambitious efforts to reshape the German group, extending his contract by three years to March 2029. The move signals strong support from the company’s supervisory board, which voted unanimously in favor of the renewal. 17 July 2025
Biotechnology
UK pharma major GSK has gained US regulatory approval for a new prefilled syringe presentation of its shingles vaccine, Shingrix (zoster vaccine), a move aimed at streamlining administration and boosting immunization coverage. 17 July 2025
Latest In Brief for AstraZeneca
Pharmaceutical
Johnson & Johnson has announced the submission of an extension of indication application to the European Medicines Agency (EMA) seeking approval of Akeega (niraparib/abiraterone acetate) with prednisone or prednisolone for the treatment of adults with metastatic hormone-sensitive prostate cancer (mHSPC) and homologous recombination repair (HRR) gene alterations. 3 July 2025
Latest Related Ones To Watch News
Once seen as a niche tool for rare tumors, theranostics is quickly becoming a new standard in cancer care. Combining diagnostics and therapy in a single platform, the field has drawn billions in pharma investment and sparked regulatory momentum, as precision imaging begins to guide not only what patients receive—but when, how often, and with what expected impact. 18 July 2025
30 June 2025
Related Ones to Watch Companies
Refine Search
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze